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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that 
accounts for about 60 to 80% of dementia cases worldwide. AD is characterized by two 
important physiological features: extracellular senile plaques consisting of β-amyloid 
(Aβ) peptide that is cleaved from a larger protein called the amyloid precursor protein 
(APP), and intracellular neurofibrillary tangles (NFTs) containing hyperphosphorylated 
tau protein. The pathogenesis of sporadic or late-onset AD (LOAD) which represents 
95% of the cases appears to not be heritable and may be related to epigenetic 
programming and environmental factors acquired earlier in life.  Apolipoprotein allele 
4 (ApoE4) protein is encoded by the ApoE gene and is considered the only established 
genetic risk factor for LOAD. It is suggested that ApoE4 affects the pathogenesis of AD 
by increasing tau hyperphosphorylation, inhibiting the clearance of amyloid-β (Aβ), and 
promoting Aβ aggregation. Perfluorooctanesulfonic acid (PFOS) is a persistent organic 
pollutant known to cause neurotoxicity and poses a major threat to the ecosystem and 
human health. The aim of this study was to investigate PFOS as a potential risk factor 
for LOAD by assessing the potential mechanism and impact of PFOS on three major 
AD-associated pathways: amyloidogenesis, tau pathology, and ApoE using in vivo and 
in vitro models.  Our findings demonstrated that SH-SY5Y neuroblastoma cells exposed 
to low concentrations of PFOS showed increased protein levels of APP, tau, and 
phosphorylated tau (p-tau) at Ser-404 and Thr-181 sites. PFOS exposure also caused an 
elevation in the kinase GSK3β, ApoE4 protein levels in vitro; however, only GSK3β 
and ApoE were modulated in vivo. These data suggest that ApoE4 is inducible by 
 
 iii  
 
environmental exposure to PFOS and may play a role in AD pathogenesis primarily by 
modulating the tau pathway via a mechanism that involves GSK3β.  
Keywords:  PFOS, ApoE4, Late-onset Alzheimer’s disease, amyloidogenic pathway, 
Tau pathology, glycogen synthase kinase-3 beta (GSK3β).  
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Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that 
accounts for about 60 to 80% of dementia cases worldwide1,2. Several pathologies have 
been implicated with AD including neuroinflammation, microglia activation, and oxidative 
stress3. The major AD hallmarks are the presence of extracellular senile plaque consisting 
of β-amyloid (Aβ) peptide that is cleaved from a larger protein called the amyloid precursor 
protein (APP), and intracellular neurofibrillary tangles (NFTs) containing 
hyperphosphorylated tau protein4. Tau is the major neuronal intracellular microtubule 
binding protein, it is essential for stabilization of microtubules, and axonal transport in 
neurons5. Hyperphosphorylated tau which occurs in pathological conditions, reduces tau 
affinity to microtubules and impairs axonal transport6,7. Several protein kinases are 
involved in the phosphorylation of tau protein such as the proline-directed protein kinases: 
cyclin-dependent kinase-5 (CDK5) and glycogen synthase kinase-3 beta (GSK3β)8. 
The etiology of Late-onset Alzheimer’s Disease (LOAD) which represents 95% of 
the cases is sporadic in nature and the only established gene associated with LOAD is 
Apolipoprotein (ApoE)9. Mounting evidence has indicated that the human ApoE gene is 
the strongest genetic risk factor for the development of LOAD10,11. The presence of one 
copy of  ApoE4 allele increases the risk of acquiring LOAD by about 3 times while the 
risk is increased by 15-fold if 2 copies of ApoE4 allele are present9,11. In the central nervous 
system (CNS), ApoE is involved with the repair process after injury10, it functions as a 
lipid transporter and/ or signaling molecule12,13. There are 3 different isoforms of ApoE in 
humans, however,  ApoE4 is the one mainly associated with increased prevalence of 




brains of AD patients15, and are detected in neurons of ApoE4 transgenic mice16. ApoE4 
appears to result in behavioral deficits and neurodegeneration through disruption of the 
cytoskeleton, stimulation of tau phosphorylation, generation of NFTs17,16,18 as well as by 
interfering in Aβ clearance thereby facilitating the aggregation of Aβ and formation of 
senile plaque9,10,11,17,19,20,21.  
The random nature of LOAD suggests that environmental factors may contribute 
to the onset of LOAD, particularly environmental exposures acquired earlier in life22.  Poly- 
and perfluoroalkyl substances (PFASs) are a class of emerging persistent organic pollutants 
(POPs) with neurotoxic properties. They are manmade fluorinated chemicals that have 
been widely used in numerous industrial and consumer products such as textile products, 
firefighting foams, and oil-resistant coatings for paper products. PFASs persist in the 
environment and bioaccumulate in the food chain 23. One of the most widely used PFASs 
is the 8-carbon chain (C8) Perfluorooctanesulfonic acid (PFOS) which has been detected 
in adult human serum24 and in children with a serum concentration equal or even higher 
than adults25. PFOS can cross the placenta, the blood brain barrier (BBB)26,27,28and was 
found in breast milk 29. PFOS strongly binds to plasma albumin30 and it has an average 
serum half-life of 5.4 years in humans 31, and 36.9 days for CD-1 mice32.  
Even though levels of PFOS exposure have decreased during the last decade due to 
industrial pashing out of PFOS, it persists in the environment due to its resistance to 
photolysis, hydrolysis, and biodegradation23. Developmental studies using rodents showed 
that exposure to PFOS can cause neural damage manifested by chronic glial activation, 
release of inflammatory factors33, altered susceptibility of the cholinergic system, resulting 




can persist into adulthood 34,35,36,37. Neonatal exposure of mice to a single PFOS dose 
21𝜇mol/kg body weight (11.3 mg/kg body weight) on PND 10 increased cerebral tau 
protein expression and caused behavioral abnormalities in adult mice 34, 37,38. Moreover, 
PFOS resulted in an increase in β-amyloid aggregation, increased tau levels, and tau 
hyperphosphorylation in adult rats39 suggesting an association between developmental 
PFOS exposure and LOAD.  
Therefore, the main aim of this study was to investigate the potential of PFOS 
exposure as a risk factor for LOAD by assessing its impact on biomarkers associated with 
three major AD-related pathways in an in vitro model using the human SH-SY5Y 
neuroblastoma cell line. Furthermore, the same pathways were examined following 






MATERIALS AND METHODS 
Animal model and PFOS exposure 
 
Twelve timed-pregnant CD-1 mice were purchased from Charles River 
Laboratories (Wilmington, MA). The pregnant dams were received on gestation day 1 
(GD)1 at the University of Rhode Island (URI) Comparative Biology Resource Center 
(CBRC). Upon arrival, the dams were weighed and housed individually in a designated 
room with controlled temperature (20-26°C), relative humidity (30-70%), and 12:12 hour 
light-dark cycle (light on at 6:00 AM; light off at 6:00 pm) where standard chow diet (SD; 
Teklad Extruded global diet, 2020X) and water were provided ad-libitum. Dams were 
randomly assigned into two treatment groups (n= 6 per treatment group) and were dosed 
with either vehicle ( 0.5% Tween-20 in deionized water) or 1 mg/kg/day PFOS (396575, 
Sigma Aldrich, St. Louis, MO) dissolved in deionized water with 0.5% Tween-20 via oral 
gavage throughout gestation (GD1-GD18 or 19 [birth]) and lactation (birth to postnatal day 
[PND] 20) as shown in figure 1.  
For dose calculation, the dams body weights were recorded every 3-4 days and the 
last dose given was on PND 19. On PND 1, neonates were randomly assigned to dams 
within the same treatment group with 10 pups assigned to each dam in order to ensure equal 
lactational PFOS exposure, excess pups were culled. On PND 20, dams and pups were 
fasted for 4-6 hours and euthanized via cardiac puncture with subsequent decapitation. The 
brain tissues were collected and stored at -80°C for biomarker assessment. During this 
study, the animals were under the supervision of the URI CBRC staff. The animal protocols 
and the study procedures were reviewed and approved by the University of Rhode Island 




Cell culture  
Human neuroblastoma SH-SY5Y cells were purchased from American Type 
Culture Collection (ATCC, Manassas, VA). Cells were cultured in Dulbecco’s Modified 
Eagle Medium (DMEM)/F12 (Invitrogen, MD) supplemented with 10% fetal bovine serum 
(FBS) (Thermo Scientific, Waltham, MA), 100 U/ml penicillin, 100 μg/ml streptomycin, 
and 2 mM L-glutamine (Sigma Aldrich, St. Louis, MO) in T-75 tissue culture flasks with 
vented lids (Cyto-one, USA Scientific) in a CO2 incubator maintained at 5% CO2 and 37°C. 
Cells were then sub-cultured at a density of 105 cells/mL into a six-well plate and upon 
80% confluency, cells were differentiated for 6 days using 10 µM all-trans retinoic acid 
(Sigma Aldrich, St. Louis, MO) dissolved in DMEM/F12 medium containing 1% FBS, 100 
U/ml penicillin, 100 μg/ml streptomycin in the dark. Cells were observed for neurite out-
growth with media being changed every 48 hours as described previously40. Furthermore, 
differentiated cells were exposed to PFOS dissolved in DMSO for 24, 48, and 72 hours at 
37°C with the following concentrations: 0, 0.001, 0.1, 5, 25, 50, 100 µM. The concentration 
of DMSO in the cell culture media was maintained at 0.1% for control and across all 
treatment groups.  
MTS assay 
The viability of differentiated SH-SY5Y human neuroblastoma cells was assessed 
after exposure to PFOS using the MTS assay kit (Promega, Madison, WI). The cells were 
seeded in 96-well plate (2 x 10 4cells/well) and treated with different concentrations of 
PFOS ranging from 0-100 µM for 24, 48, and 72 hours. After the completion of the 
incubation period, the media containing PFOS was aspirated out and fresh media with no 




were incubated at 37°C for 2 hours and after incubation, the absorbance was measured at 
490nm by using the Spectramax M2 Multi-mode microplate reader (Molecular Devices, 
San Jose, CA). 
Protein Extraction and Western Blotting 
The brain cortex samples and cells were lysed using radio-immunoprecipitation 
assay (RIPA) lysis buffer (Sigma Aldrich, MO) supplemented with phosphatase and 
protease inhibitor tablet: one tablet was dissolved in 10 ml of RIPA buffer (Pierce Protease 
and Phosphatase Inhibitor Mini Tablets, EDTA-Free, Thermo Scientific, Waltham, MA). 
The samples were incubated on ice for 30 min, then vortexed and sonicated for 5 minutes. 
The samples were subsequently centrifuged at 10,000 g for 20 min and the supernatants 
were collected and stored at -80C for protein quantification and western blot analysis. The 
protein concentration was determined using Micro BCA protein assay kit (Thermo 
Scientific, Waltham, MA). For western, at least 20 µg of total protein was first separated 
by sodium dodecyl sulfate polyacrylamide gels (SDS-Page) on 4-15% Mini-protean® 
TGXTM precast gels (Bio-Rad, Hercules, CA), and then transferred to polyvinylidene 
fluoride (PVDF) membranes (GE-Healthcare, Piscataway, NJ). The membranes were 
blocked for 1 hour at room temperature with gentle agitation in blocking buffer comprising 
5% (w/v) bovine serum albumin (BSA) in Tris-Buffered saline with 0.1% Tween-20 
(TBST, pH 7.4).  
Immunoblotting was then performed by incubating the membranes with gentle 
agitation on a shaker overnight at 4C with primary antibodies of interest: Rabbit Anti-
ApoE (Thermo Scientific, Waltham, MA), Mouse Anti-ApoE4, Mouse Anti-Tau-46, 




Anti-APP (Cell Signaling Technology, MA) at a dilution of 1:1000 in TBST. On the 
following day, the membranes were washed three times with TBST for 5 min each and 
exposed at room temperature for 1 hour to either goat anti-mouse or goat anti-rabbit 
IRDye® 680 or 800 LT infrared dye (LI-COR Biotechnology, Lincoln, NE) at a 1: 10,000 
dilution factor in TBST then the membranes were again washed three times with TBST. 
Also, the specific target protein/GAPDH ratio was obtained by re-probing the membranes 
for 2 hours at room temperature with primary antibody for the protein Glyceraldehyde 3-
phosphate dehydrogenase (Rabbit Anti-GAPDH) at 1:5,000 dilution as a control, followed 
by washing and re-exposure to goat anti-rabbit IRDye® 680 or 800 LT infrared dye (LI-
COR Biotechnology, Lincoln, NE) at a 1: 10,000 dilution factor in TBST (Cell Signaling 
Technology, MA). Finally, images were captured using the Odyssey® Infrared Imaging 
System (Li-Cor, NE), and Band intensities were measured using NIH ImageJ software and 
normalized against GAPDH.  
Total RNA isolation, synthesis of cDNA, and RT-q PCR 
Total RNA was isolated from cerebral cortex tissues and the SH-SY5Y cells using 
the TRIzol reagent method (Invitrogen, Carlsbad, CA). The integrity of the isolated RNA 
was verified by NanoDrop (Thermo Scientific, Wilmington, DE) analysis. The 
complementary DNA (cDNA) was then synthesized following the manufacturer’s 
instruction by using the iScriptTM Select cDNA synthesis kit (Bio-Rad, Hercules, CA). The 
reaction mixture consisted of 1µg of RNA diluted in 4 µl 5X iScript reaction mix, 1 µl 
iScript reverse transcriptase in a total volume of 20 µl of RNA free water. Using MJ 




minutes using the following protocol, Priming for 5 min at 25C, reverse transcription at 
46 C for 20 min, RT inactivation 1 min at 95 C.  
Primer pairs for mouse tau, APP, GSK3β, CDK5, GAPDH and human tau, APP, 
GSK3β, CDK5 and GAPDH were obtained from integrated DNA Technologies IDT 
(Coralville, IA, USA) as follows: mouse tau F: 5’-CCTGAGCAAAGTGACCTCCAAG-
3’; and tau R: 5’-CAAGGAGCCAATCTTCGACTGG-3’; mouse APP F: 5’-TGCAGC 
AGAACGGATATGAG-3’; and APP R: 5’-ACACCGATGGGTAGTGAAGC-3’; mouse 
GSK3β F: 5’-AGGAAGGAAAAGGTGATTCAAGA-3’; and GSK3β R: 5’-TGCTGCCA 
TCTTTATCTCTGCT-3’; mouse CDK5 F: 5’-GGGACCTGTTGCAGAACCTAT-3’; and 
CDK5 R: 5’-AGTCAGAGAAGTAGGGGTGCT-3’; mouse GAPDH F: 5’-TGGTGA 
AGCAGGCATCTGAG-3’; and GAPDH R: 5’-TGCTGTTGAAGTCGCAGGAG-3; 
human tau F: 5’-TGAACCAGGATGGCTGAGC-3’, and tau R: 5’-TTGTCATCGCTTC 
CAGTCC-3’; human APP F: 5’-CTGTGGCAGACTGAACATGC-3’, and APP R: 5’-
TGTTCAGAGCACACCTCTCG-3’; human GSK3β F: 5’- GGATTCGTCAGGAACAG 
GACA-3’, and GSK3β R: 5’-AGTATTAGCATCTGACGCTGC-3’; human CDK5 F: 5’-
GATGATGAGGGTGTGCCGAG-3’, and CDK5 R: 5’-TGCGGCTATGACAGAATCC 
C-3’; human GAPDH F: 5’-AGGTCGGAGTCAACGGATTT-3’, and GAPDH R: 5’-
TTCCCGTTCTCAGCCTTGAC-3’. Real-time PCR was carried out in 20 µl reaction 
volumes containing 1 µl of each forward and reverse primers, 1 µl of cDNA, 7 µl of 
nuclease-free water, and 10 µl of SYBR® Green PCR Master Mix (Applied Biosystems, 
Foster City, CA). The qPCR reaction was performed following the standard protocol: 
samples were incubated for 2 min at 50°C, then for 10 min at 95°C, followed by 15 seconds 




(Applied Biosystems, Foster City, CA). GAPDH mRNA expression was used as the 
endogenous control and the data was reported using the 2-ΔΔCT method.     
Enzyme Linked Immunosorbent Assay (ELISA)   
Cortex tissues were weighed and homogenized in eight volumes of an ice-cold 
solution containing 5 M guanidine HCl dissolved in 50 mM Tris-HCl, PH 8.0 (Sigma 
Aldrich, St. Louis, MO). The mixture was maintained for 3-4 hours at room temperature 
and then diluted with ice-cold Phosphate buffer saline (PBS) supplemented with 1X 
protease and phosphatase inhibitor (Thermo Scientific, Waltham, MA) until reaching a 
final concentration of 0.1 M guanidine. The samples were centrifuged for 20 minutes at 
16,000 g at 4°C and the resulting supernatant was maintained either on ice for Aβ 
quantification or stored at -80°C for later use. ELISA kit catalog numbers KMB3441 and 
KMB3481 (Thermo Scientific, Waltham, MA) were used according to the manufacturer’s 
instruction for quantification of Aβ1-42 and Aβ1-40 respectively.  
These ELISA kits contain a colorimetric detection with double ELISA antibody 
approach. In each kit, the N-terminus of the mouse Aβ is determined by the monoclonal 
antibody coated in the wells. The Standards (provided in the kit) and the samples containing 
the Aβ antigen were added to the wells with the appropriate dilution (100 µl in each well). 
The plates were maintained at room temperature for 2 hours to allow the binding of the 
immobilized (capture) antibody and the Aβ antigen. Then, the plates were washed four 
times by using the washing solution provided in the kit. Subsequently, a solution of rabbit 
antibody specific for the C-terminus of either Aβ1-42 or Aβ1-40 was added to the wells (100 
µl in each well) except for the blanks. The plates were then covered and incubated again 




washing solution and 100 µl of horseradish-peroxidase-labeled anti-rabbit antibody was 
added to each well except for the blanks. Then, the plate was covered and incubated at 
room temperature for 30 minutes followed by four times washing. Then, 100 µl of the 
stabilized chromogen solution was added to each well and the plate was incubated at room 
temperature for 20-30 minutes in the dark. Once, the reaction mixtures turned blue, 100 µl 
per well of the stop solution was added to each well to stop the reaction and the mixture 
turned yellow. Finally, the absorbance was detected at 450 nm using the Spectramax M2 
Multi-mode microplate reader (Molecular Devices, San Jose, CA) 
Statistical analysis  
The results of various exposed groups versus the control were expressed as the 
mean ± the standard error of the mean (SEM). The data were analyzed by using the 
statistical tests: unpaired two-tailed Student's t-test for comparison between two groups and 
the one-way analysis of variance (ANOVA) followed by the Dunnett or Tukey test for 
multigroup comparisons. The GraphPad Prism 8.0 computer software (La Jolla, CA, USA) 
was used for the analysis, and p-value < 0.05 was considered to indicate a statistically 








Effects of PFOS exposure on SH-SY5Y cell viability 
Differentiated SH-SY5Y cells were exposed to a series of PFOS concentrations (0, 
0.001, 0.1, 1, 5, 25, 50, 100 µM) and cell viability was determined using the MTS assay 
following 24, 48, and 72 h of exposure. At 24h, There was no significant cytotoxicity 
observed. However, at 48 (100 µM) and at 72 h (25, 50, 100 µM) concentrations of PFOS 
revealed significant decreases in cell viability (p= 0.05, p< 0.001). Thus, PFOS exposure 
at concentrations (0.001, 0.1 µM) for 24 h were considered appropriate for further studies 
(Figure 2).   
PFOS effects on APP mRNA and protein levels in differentiated SH-SY5Y cells. 
(amyloidogenic pathway)  
Further, we investigated the effects of PFOS on AD biomarkers related to the 
amyloidogenic pathway in human neuroblastoma SH-SY5Y cells. APP protein level was 
significantly elevated as compared to the control after 24 h exposure to 0.001 µM 
concentration of PFOS, p= 0.0152 (Figure 3A, B). We did not observe any effects on APP 
mRNA levels (Figure 3C).  
PFOS effects on Tau mRNA expression, Total Tau, and P-tau protein levels in 
differentiated SH-SY5Y cells (tau Pathway) 
SH-SY5Y cells showed a significant increase in total tau, P-tau (Ser-404) and P-
tau (Thr-181) protein levels as compared to controls after 24 h exposure to 0.001 µM of 
PFOS, P= 0.0307, P= 0.0062, P=0.036 respectively (Figure 4A, B, D-G). Also, P-tau (Ser-
404) was significantly elevated as compared to controls in SH-SY5Y cells after 24 h 




was no effect of PFOS exposure on total tau mRNA expression (Figure 4C). Next, we 
investigated the effect of PFOS on kinase pathways in differentiated SH-SY5Y cells. 
GSK3β protein levels were significantly increased as compared to controls following 24 h 
exposure of SH-SY5Y cells to PFOS at 0.001 µM concentration, p=0.012 analyzed by the 
one-way ANOVA (Figure 5A, B). We did not observe any significant changes in CDK5 
protein levels and mRNA expression levels of GSK3β and CDK5 (Figure 5C-F), based on 
a one-way ANOVA followed by Dunnett’s for multiple comparisons. 
PFOS effects on ApoE and ApoE4 protein levels in differentiated SH-SY5Y cells 
(Non-neural Pathway) 
We further analyzed the impact of PFOS exposure on non-neural pathways 
associated with AD. SH-SY5Y cells exposed to PFOS at 0.001 µM concentration for 24 h, 
showed a significant increase in ApoE4 protein levels as compared to controls, P= 0.026 
(Figure 6C, D) analyzed by the one-way ANOVA followed by Dunnett’s for multiple 
comparisons. Interestingly, PFOS had no effect on total ApoE protein levels in SH-SY5Y 
exposed cells at 0.001 and 0.1 µM concentrations following 24 h of exposure (Figure 6A, 
B).  
Effects of developmental exposure of PFOS on APP mRNA expression, APP protein 
levels, Aβ1-42 and Aβ1-40 accumulation (amyloidogenic pathway) 
We observed an increasing trend in the effect of PFOS exposure on APP mRNA 
expression and APP protein levels as compared to controls (Figure 7A-C). PFOS exposure 
caused an increased trend in Aβ42 and the ratio of Aβ42/Aβ40 proteins levels, however, these 





Effects of developmental PFOS exposure on Tau mRNA expression, Total Tau and 
P-tau protein levels (tau Pathway) 
Tau mRNA expression in the cortex of PFOS exposed group showed no significant 
difference as compared to controls (Figure 8C). Western blot analysis showed no 
significant difference between the PFOS exposed group and the control group in Total tau 
and P-tau (Ser-404) protein levels (Figure 8A, B, D, E). The protein level of P-tau (Thr-
181) was trending higher in the PFOS exposed group compared to controls (Figure 8F, G). 
The PFOS exposed group showed a significant increase in GSK3β protein levels as 
compared to control group, p= 0.05 determined by two-tailed unpaired t-test (Figure 9A, 
B). The GSK3β mRNA expression was trending higher in the PFOS exposed group 
compared to controls (Figure 9C). We did not observe any significant effects on CDK5 
mRNA expression and protein levels in the PFOS treated group compared with the control 
group (Figure 9D-F).  
Effects of developmental PFOS exposure on ApoE protein levels (Non-neural 
Pathway) 
Western blot analysis showed that PFOS significantly increased total ApoE protein 
levels in brain cortex as compared to the control group, p= 0.0025 analyzed by two-tailed 















As a persistent organic pollutant, PFOS has been identified as a developmental 
neurotoxicant24,41,42. Previous studies have reported the developmental effects of PFOS on 
neurological disorders, behavioral disorders, and cognitive function35,43,44.  A few reports 
indicated that developmental exposure to PFOS induced tau protein levels37 and enhanced 
AD pathological hallmarks45. However, the effects of PFOS on amyloidogenic, tau, kinase, 
and non-neural pathways related to AD are not fully elucidated in the literature. 
Previous work from our lab has demonstrated that developmental exposure to 
environmental toxins such as lead (Pb) induced cognitive deficits, latent overexpression of 
tau, and phosphorylated tau in the adult rodents cortex46,47. In addition, differentiated 
human neuroblastoma cells (SH-SY5Y) exposed to a series of Pb concentrations (0-100 
µM) for 48 h showed an alteration in tau and hyperphosphorylation of tau48. Therefore, we 
performed in vivo and in vitro studies to investigate potential PFOS impacts on AD related 
biomarkers and pathways. 
The present study established that the concentrations range of PFOS (0-100 µM) 
had no significant cytotoxicity on differentiated SH-SY5Y cells following 24 h of exposure 
(Figure 2), and revealed that PFOS may impact the amyloidogenic pathway which was 
indicated by elevation of amyloid precursor protein (APP) levels (Figure 3A, B) at 0.001 
µM of PFOS in SH-SY5Y cells. Furthermore, overexpression of tau and site-specific 
hyperphosphorylation of tau (Ser-404 and Thr181) proteins were both induced by PFOS in 
SHSY5Y cells at very low concentrations (0.001and 0.1 µM) (Figure 4A, B, D-G) 
providing more evidence that PFOS can promote AD pathogenesis through modulating the 




(P-tau) proteins are responsible for the loss of microtubule stability and axonal transport in 
AD49,50. This is consistent with the study by Zhang et al (2016) which reported that 
developmental exposure to PFOS induced β-amyloid aggregation, total tau, and 
phosphorylated tau proteins levels in adult rats at PND 9045. Also, Johansson et al (2009) 
reported that neonatal mice exposed to a single PFOS dose on PND 10 showed a significant 
elevation of cerebral tau protein levels37. This is consistent with our data suggesting the 
impact of PFOS on amyloidogenic and tau pathways related to AD.  
Moreover, we investigated the effect of PFOS on the kinase pathways that are 
associated with AD. GSK3β is an active serine/threonine proline-directed kinase, it is 
involved in many processes including inflammatory responses, memory impairment, 
cholinergic deficits, increased the production of Aβ and hyperphosphorylation of tau51. 
Also, the sites of tau phosphorylation found in AD brain are proline-directed (Thr-Pro or 
Ser-Pro). Thus, GSK3β plays an important role in the pathogenesis of AD52. In this study, 
we observed the ability of PFOS to promote an increase in the GSK3β protein levels at 
very low concentrations (0.001 µM; Figure 5A, B). There was no effect observed on CDK5 
(Figure 5D-F).  
In addition to the most common neural pathways associated with AD, this study to 
our knowledge is the first study to investigate the effect of PFOS on non-neural pathways 
associated with AD, namely Apolipoprotein E (ApoE). It has been reported that ApoE4 
can stimulate the phosphorylation of tau and the generation of NFTs18 as well as facilitating 
the aggregation of Aβ and formation of senile plaque9,10,11,17. Also, a recent in vitro study 
indicated that GSK3β activity can be upregulated by ApoE4 through the inhibition of the 




LRP6) receptors53. The invitro work here showed that PFOS exposure at 0.001 µM for 24 
h increased ApoE4 protein levels significantly (Figure 6C, D). It is worth noting here that 
our in vivo findings did not demonstrate that PFOS exposure alters amyloidogenic and tau 
pathways in wild-type CD-1 mice on PND 20 (Figure 7 and 8). Similar to previous 
developmental behavioral study by Butenhoff et al 2009 indicated that rat offspring 
exposed from GD0 to PND 20 to 1 mg/kg/day PFOS didn’t show any changes in learning 
and memory abilities on PND 2054.  However, this is in contrast with what was previously 
published by Zhang et al 2016 and Johansson et al 2009. Thereby, It should be pointed out 
that in our study PFOS was given to dams via oral gavage and we focused on perinatal 
exposure of pups to PFOS during gestation and lactation till PND 20, the study by Zhang 
et al 2016 the dams were given PFOS in drinking water and they studied both perinatal 
exposure of pups and direct exposure till PND 90. Therefore, the complex physiological 
activities during the brain developmental stages including the brain growth spurt (BGS) 
and the establishment of the BBB, as well as the experimental design, time points, animal 
model, and the duration of exposure might explain the differences in the findings.  
Furthermore, our in vivo data showed that developmental exposure to PFOS caused 
a significant increase in GSK3β protein levels (Figure 9A, B).  PFOS resulted in a 
significant elevation of ApoE protein levels in the cerebral cortex of wild-type CD-1 mice 
(Figure 10A, B). It is noteworthy here that humans express 3 isoforms of ApoE (h-ApoE) 
protein while mice express only one isoform (m-ApoE)55. The homology of the amino acid 
sequences between the h-ApoE and the m-ApoE is only 70%. Although m-ApoE contains 
the equivalent Arg112/Arg158 residues present in h-ApoE4, several studies have indicated 




while m-ApoE functions as a single domain protein56. However, it has been demonstrated 
that the m-ApoE is involved in Aβ amyloid deposition in APP transgenic (Tg) mice that 
develop Aβ aggregation57,58.  
Although our in vivo and in vitro findings indicated changes in the protein levels of key 
biomarkers related to major AD associated pathways, PFOS caused no changes in the 
mRNA expression of these biomarkers in disagreement with Zhang el at 2016 and 
others35,59,60 possibly due to differences in the study design as mentioned above. It is also 
worth noting that effects of PFOS exposure were mainly in the lower concentrations range 
and for a short duration (24 hours), consistent with previous studies on other cell types that 
described the dose-response curve of PFOS as a bell-shaped and non-monotonic35,61. Liao 
et al (2008) reported that 1 µM of PFOS resulted in an increase of glutamate-activated 
current while 100 µM showed a suppressive effect in cultured primary hippocampal 
neurons62. Additionally, it was indicated that the effects of PFOS exposure on other cell 
types such as HAPI microglial cells and glioma cells generally reach a peak in short periods 
and then decline suggesting that the cultured cells may develop tolerability to PFOS by 
some mechanisms63,64. It is worth noting here that this study has limitations.  Transgenic 
mice with human APP, Tau, and expressing human ApoE isoforms would further elucidate 
the mechanism by which PFOS exposure induces AD pathogenesis. Additionally, studying 
the effect of PFOS exposure on other CNS cells such as microglia and astrocytes can 
further recapitulate the impact of PFOS on ApoE and to understand the mechanism of 





The results presented herein suggest that PFOS impacts amyloidogenic, tau, and 
kinase pathways related to AD particularly in human cells through the upregulation of 
ApoE4 protein levels via a mechanism associated with GSK3β. This study may contribute 
to understanding the mechanism by which PFOS triggers AD pathogenesis. However, 
further investigation is warranted such as examination of potential involvement of 
phosphatase enzymes, microRNA, cellular degradation pathways including insulin 
degrading enzymes in the mechanism of PFOS to further confirm these findings and to 
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Figure 1. Scheme of PFOS exposure in timed-pregnant CD-1 mice. Pregnant mice were 
given either 1 mg/kg/day PFOS in water with 0.5% Tween-20 or vehicle (0.5% Tween-20 
in water) via oral gavage throughout gestation (GD1-GD18 or 19 [birth]) and lactation 
(birth to postnatal day [PND] 20). Brain tissues were collected from pups at PND 20 (n=4 











































Figure 2. Effects of PFOS exposure on SH-SY5Y cells viability. Cells were exposed to 
a series of PFOS concentrations (0, 0.001, 0.1, 1, 5, 25, 50, 100 µM) for 24, 48 and 72 h 
followed by MTS assay. Data are expressed as mean ± S.E.M using the one-way ANOVA 


































Figure 3. APP mRNA and protein levels in differentiated SH-SY5Y cells after PFOS 
exposure (amyloidogenic pathway). Differentiated SH-SY5Y cells exposed to PFOS at 
0.001 and 0.1 µM concentrations for 24 h. (A-B) quantification of APP protein levels 
normalized to GAPDH. (C) APP mRNA levels. Results are expressed as mean ± S.E.M 
using the one-way ANOVA followed by Dunnett’s for multiple comparisons, n=3 (*P< 





































Figure 4. Tau mRNA and protein levels in differentiated SH-SY5Y cells after PFOS 
exposure (tau pathway). Differentiated SH-SY5Y cells exposed to PFOS at 0.001 and 0.1 
µM concentrations for 24 h. (A-B) quantification of Tau protein levels normalized to 
GAPDH. (C) Tau mRNA levels. (D-E) quantification of p-tau (ser404) protein levels 
normalized to GAPDH. (F-G) quantification of p-tau (Thr 181) protein levels normalized 
to GAPDH. Results are expressed as mean ± S.E.M using the one-way ANOVA followed 

































Figure 5. GSK3β, CDK5 mRNA, and protein levels in differentiated SH-SY5Y cells 
after PFOS exposure (kinase pathway). Differentiated SH-SY5Y cells exposed to PFOS 
at 0.001 and 0.1 µM concentrations for 24 h. (A-B) quantification of GSK3β protein levels 
normalized to GAPDH. (C) GSK3β mRNA levels. (D-E) quantification of CDK5 protein 
levels normalized to GAPDH. (F) CDK5 mRNA levels. Results are expressed as mean ± 
S.E.M using the one-way ANOVA followed by Dunnett’s for multiple comparisons, n=3 





























Figure 6. ApoE protein levels in differentiated SH-SY5Y cells after PFOS exposure 
(non-neural pathway). Differentiated SH-SY5Y cells exposed to PFOS at 0.001 and 0.1 
µM concentrations for 24 h. (A-B) quantification of ApoE protein levels normalized to 
GAPDH. (C-D) quantification of ApoE4 protein levels normalized to GAPDH. Results are 
expressed as mean ± S.E.M using the one-way ANOVA followed by Dunnett’s for multiple 
































Figure 7. APP mRNA and protein levels at PND 20 in the cortex of CD-1 pup mice 
developmentally exposed to PFOS (amyloidogenic pathway). Timed-pregnant female 
CD-1 mice were administered with vehicle (0.5% Tween-20 in water) or 1 mg/kg/day 
PFOS in water with 0.5% Tween-20 via oral gavage from gestation GD1 through postnatal 
day PND 20.  (A-B) quantification of APP protein levels normalized to GAPDH. (C) APP 
mRNA levels. (D-E) quantification of Aβ 1-42 and Aβ 1-40 protein levels normalized to 
GAPDH. (F) Aβ 1-42: Aβ 1-40 ratio.  Results are expressed as mean ± S.E.M using the 































Figure 8. Tau mRNA and protein levels at PND 20 in the cortex of CD-1 pup mice 
developmentally exposed to PFOS (tau pathway). Timed-pregnant female CD-1 mice 
were administered with vehicle (0.5% Tween-20 in water) or 1 mg/kg/day PFOS in water 
with 0.5% Tween-20 via oral gavage from gestation GD1 through postnatal day PND 20.  
(A-B) quantification of Tau protein levels normalized to GAPDH. (C) Tau mRNA levels. 
(D-E) quantification of p-tau (ser404) protein levels normalized to GAPDH. (F-G) 
quantification of p-tau (Thr 181) protein levels normalized to GAPDH. Results are 
expressed as mean ± S.E.M using the two-tailed unpaired t-test, n=4. Results don’t indicate 

































Figure 9. GSK3β, CDK5 mRNA levels and protein levels at PND 20 in the cortex of 
CD-1 pup mice developmentally exposed to PFOS (kinase pathway). Timed-pregnant 
female CD-1 mice were administered with vehicle (0.5% Tween-20 in water) or 1 
mg/kg/day PFOS in water with 0.5% Tween-20 via oral gavage from gestation GD1 
through postnatal day PND 20.  (A-B) quantification of GSK3β protein levels normalized 
to GAPDH. (C) GSK3β mRNA levels. (D-E) quantification of CDK5 protein levels 
normalized to GAPDH. (F) CDK5 mRNA levels. Results are expressed as mean ± S.E.M 

































Figure 10. ApoE protein levels at PND 20 in the cortex of CD-1 pup mice 
developmentally exposed to PFOS (non-neural pathway). Timed-pregnant female CD-
1 mice were administered with vehicle (0.5% Tween-20 in water) or 1 mg/kg/day PFOS in 
water with 0.5% Tween-20 via oral gavage from gestation GD1 through postnatal day PND 
20. (A-B) quantification of ApoE protein levels normalized to GAPDH. Results are 
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